Notice of Clarification of Research Areas Included in PAR-16-106 “Rapid Assessment of Zika Virus (ZIKV) Complications (R21)”

Notice Number: NOT-NS-16-027

Key Dates
Release Date:  May 27, 2016

Related Announcements
PAR-16-106 

Issued by
National Institute of Neurological Disorders and Stroke (NINDS)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Dental and Craniofacial Research (NIDCR)
National Eye Institute (NEI)
National Institute of Biomedical Imaging (NIBIB)
National Heart, Lung, and Blood Institute (NHLBI)
Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs (ORIP)

Purpose

The purpose of this Notice is to clarify areas of high priority research that are included in the focus of the funding opportunity announcement PAR-16-106, "Rapid Assessment of Zika Virus (ZIKV) Complications (R21)".  At the time of publication of this funding opportunity announcement, data was not yet available on the association of ZIKV with Guillain-Barré Syndrome (GBS) and other neurological complications in adults.  Now that such data is emerging, this Notice is intended to amend the list of possible areas of high priority to include:

  • Studies of Guillain-Barré Syndrome (GBS), encephalitis or encephalomyelitis associated with ZIKV infection to determine disease course and outcomes, causality, disease mechanisms, effectiveness of current treatments and to develop novel treatments.
  • This Notice is also intended to encourage immunologists to apply their expertise to understanding and treating immune mechanisms of ZIKV-associated GBS or other neurological complications.

All other aspects of the FOA remain the same.

Inquiries

Please direct all inquiries to:

May Wong, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone:  301-496-1431
Email:  wongm@ninds.nih.gov